2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve Cannabis and Cronos Group have both gained approximately 27% in 2026, outpacing the S&P 500's 12% gain. Trulieve, now listed on the NYSE, generated $74 million in free cash flow in H1 2026 with a 60% gross margin. Cronos delivered 58% year-over-year revenue growth to $53 million in Q2 with expanding margins and $827 million in cash, while also returning capital to shareholders through share buybacks.